- Chemicals for Life Science -

To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.

Home > RNA Delivery > Cationic/Ionizable Lipids

DM3-BTA-14

Cat. No.: DC67537 Featured

Chemical Structure

For research use only. We do not sell to patients.

We match the best price and quality on market.
Email:order@dcchemicals.com sales@dcchemicals.com
Tel:+86 21 58447131

Get Quotation Now

We are official vendor of:

More than 5000 active chemicals with high quality for research!

Field of application

DM3-BTA-14 is a cationic lipid compound engineered for high-efficiency mRNA delivery developed by Hefei AlphaNA Biotechnology. Its structure features a rigid benzene-1,3,5-tricarboxamide core linked to a protonatable dimethylamino headgroup (-N(CH₃)₂) via a propylene spacer (-CH₂CH₂CH₂-) and two saturated C14 alkyl chains. This design enables ≈90% endosomal escape efficiency , superior lymph node targeting for vaccines , and effective tumor-specific mRNA delivery . It outperforms benchmark lipids while maintaining low cytotoxicity, forming stable nanoparticles with cholesterol/DSPC/DSPE-PEG (50:39:10:1 ratio) for therapeutic applications.

Chemicals Properties Biological activity Related products COA MSDS Datasheet

Cas No.:
Chemical Name:	DM3-BTA-14
Synonyms:	DM3BTA14， DM3 BTA 14
SMILES:	CCCCCCCCCCCCCCOC(=O)C1=CC(C(=O)OCCCCCCCCCCCCCC)=CC(C(=O)NCCCNC)=C1
Formula:	C₄₁H₇₂O₅N₂
M.Wt:	672.54
Purity:	ELSD-HPLC>95%
Sotrage:	1 year -20°C

Cat. No.	Product name	Field of application
DC67537	DM3-BTA-14	DM3-BTA-14 is a cationic lipid compound engineered for high-efficiency mRNA delivery developed by Hefei AlphaNA Biotechnology. Its structure features a rigid benzene-1,3,5-tricarboxamide core linked to a protonatable dimethylamino headgroup (-N(CH₃)₂) via a propylene spacer (-CH₂CH₂CH₂-) and two saturated C14 alkyl chains. This design enables ≈90% endosomal escape efficiency , superior lymph node targeting for vaccines , and effective tumor-specific mRNA delivery . It outperforms benchmark lipids while maintaining low cytotoxicity, forming stable nanoparticles with cholesterol/DSPC/DSPE-PEG (50:39:10:1 ratio) for therapeutic applications.

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

DM3-BTA-14​​

DM3-BTA-14